s silver dihydrogen citrate-based
antimicrobials, represent innovative advances in diverse markets and lead
today's global trend toward industry and consumer use of "green" products
while providing competitive advantages in efficacy and safety. Patented SDC
is an electrolytically generated source of stabilized ionic silver which
formulates well with other compounds. As a platform technology, SDC is
distinguished from competitors in the marketplace because of its superior
efficacy, reduced toxicity and the inability of bacteria to form a
resistance to it. PURE is headquartered in El Cajon, California (San Diego
metropolitan area). Additional information on PURE is available at
http://www.purebio.com.
This press release includes statements that may constitute "forward-
looking" statements, usually containing the words "believe," "estimate,"
"project," "expect" or similar expressions. These statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially from the
forward-looking statements. Factors that would cause or contribute to such
differences include, but are not limited to, acceptance of the Company's
current and future products and services in the marketplace, the ability of
the Company to develop effective new products and receive regulatory
approvals of such products, competitive factors, dependence upon
third-party vendors, and other risks detailed in the Company's periodic
report filings with the Securities and Exchange Commission. By making these
forward-looking statements, the Company undertakes no obligation to update
these statements for revisions or changes after the date of this release.
Investor Contact:
Terri MacInnis, Bibicoff & Associates, Inc.
818-379-8500
SOURCE PURE Bioscience Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Perscitus Biosciences secures $250K Commerce loan2.
Wisconsin biosciences rise to the challenge3.
Quintessence Biosciences advances cancer drug4.
Bioscience clusters: Too many or room for more?5.
Quintessence Biosciences names new president6.
Caden Biosciences may signal critical mass7.
Wisconsin start up Primorigen Biosciences corrals out-of-state investment8.
WARF signs licensing pact with BD Biosciences9.
Fisher Biosciences contracts with Madison-based GenTel BioSurfaces10.
Bioscience beats beer11.
State awards QRG Biosciences development grant